TYENNE 162 mg/.9mL
Tocilizumab-aazg · INJECTION, SOLUTION · Fresenius Kabi USA, LLC
No Recall History
Plain English
TYENNE is a injection, solution containing tocilizumab-aazg at 162 mg/.9mL, taken subcutaneous. Manufactured by Fresenius Kabi USA, LLC.
Key Facts
- Brand Name
- TYENNE
- Generic Name
- Tocilizumab-aazg
- NDC Code (Product)
65219-586- Manufacturer
- Fresenius Kabi USA, LLC
- Strength
- 162 mg/.9mL
- Dosage Form
- INJECTION, SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761275
- Drug Class
- Interleukin-6 Receptor Antagonist [EPC]
- Marketing Start
- 07/01/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is TYENNE used for?
TYENNE contains Tocilizumab-aazg. It is a injection, solution taken subcutaneous. Consult your doctor for specific uses.
Is TYENNE a controlled substance?
TYENNE is not classified as a controlled substance by the DEA.
What is the generic name for TYENNE?
The generic name for TYENNE is Tocilizumab-aazg. There are no other listed brand versions of Tocilizumab-aazg.
What is the NDC code for TYENNE 162 mg/.9mL?
The NDC (National Drug Code) for TYENNE 162 mg/.9mL is 65219-586, listed by Fresenius Kabi USA, LLC.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)